Study outlines benefits of dapagliflozin on renal outcomes in people with type 2 diabetes

Study outlines benefits of dapagliflozin on renal outcomes in people with type 2 diabetes

Initiating dapagliflozin can improve kidney function outcomes and albuminuria in people with type 2 diabetes who have a low renal risk, latest evidence suggests.

Despite the overall improvement in care, people with type 2 diabetes do experience an excess risk of end-stage kidney disease.

During the study, the team of researchers examined the health outcomes of two matched groups, which consisted of 6,197 people in each. This included people with type 2 diabetes who initiated dapagliflozin or comparators from 2015 to 2020.

Propensity score matching (PSM) was performed by the researchers to balance the two groups. The primary endpoint was to analyse the change in estimated glomerular filtration rate (eGFR) from baseline to the end of observation. Secondary endpoints included changes in albuminuria and loss of kidney function.

The comparator group included DPP-4 inhibitors (40 per cent), GLP-1RA (22.3 per cent), sulphonylureas (16.1 per cent), pioglitazone (eight per cent), metformin (5.8 per cent), or acarbose (four per cent).

The results state: “Only 6.4 per cent had baseline eGFR <60 ml/min/1.73 m2 and 15 per cent had UACR >30 mg/g.

“During a mean follow-up of 2.5 year, eGFR declined significantly less in the dapagliflozin vs comparator group by 1.81 ml/min/1.73 m2 (95 per cent C.I. from 1.13 to 2.48; p < 0.0001).

“The mean eGFR slope was significantly less negative in the dapagliflozin group by 0.67 ml/min/1.73 m2/year (95 per cent C.I. from 0.47 to 0.88; p < 0.0001).”

The findings added: “Albuminuria declined significantly in new-users of dapagliflozin within 6 months and remained on average 44.3 mg/g lower (95 per cent C.I. from −66.9 to −21.7; p < 0.0001) than in new-users of comparators.

“New-users of dapagliflozin had significantly lower rates of new-onset chronic kidney disease, loss of kidney function, and a composite renal outcome.

“Results were confirmed for all SGLT2 inhibitors, in people without baseline chronic kidney disease, and when GLP-1RA were excluded from comparators.”

To read the study, click here.

Author: Philip Lopez